<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/728636B0-61D3-4346-9055-309321344A27"><gtr:id>728636B0-61D3-4346-9055-309321344A27</gtr:id><gtr:name>Eurovacc Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/81695DA5-EA6A-42F9-82FD-9474811ED875"><gtr:id>81695DA5-EA6A-42F9-82FD-9474811ED875</gtr:id><gtr:name>National Institute of Virology Johannesburg</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/728636B0-61D3-4346-9055-309321344A27"><gtr:id>728636B0-61D3-4346-9055-309321344A27</gtr:id><gtr:name>Eurovacc Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/81695DA5-EA6A-42F9-82FD-9474811ED875"><gtr:id>81695DA5-EA6A-42F9-82FD-9474811ED875</gtr:id><gtr:name>National Institute of Virology Johannesburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5"><gtr:id>B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5</gtr:id><gtr:firstName>Pontiano</gtr:firstName><gtr:surname>Kaleebu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950097145"><gtr:id>413CB829-B57A-4EDF-91B9-8954919B4582</gtr:id><gtr:title>Basic Science Programme / Research aimed at designing an effective HIV vaccine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950097145</gtr:grantReference><gtr:abstractText>One of the challenges of developing an HIV vaccine is the poor understanding of the protective immune responses that could be used to design a vaccine. We use data and blood specimens from different cohorts of the MRC/UVRI Uganda Unit to look for possible protective immune responses, for example by trying to understand why some individuals who are exposed to the virus remain uninfected or why some individuals who are infected progress to AIDS faster than others. We have also initiated studies aimed at identifying the best vectors to use in HIV vaccine design especially after one HIV vaccine trial found that use of so-called Ad5 vectors might be risky. (A vaccine vector is another virus that is in itself harmless and can be used to introduce the specific HIV vaccine antigen into the human body in order to trigger an immune response). Finally we participate in HIV vaccine trials performing safety and immunogenicity assays. The laboratory assays used include elispot assays, flowcytometry and neutralization assays among others.</gtr:abstractText><gtr:technicalSummary>Overall aim: To contribute to better understanding of HIV protective immunity and vaccine design. Specific objectives are a) to study immunological correlates of protection in exposed sero negative individuals (ESN), ii) to characterize immune responses among individuals with different viral set points in early/acute HIV infection, iii) to investigate correlates of protection from HIV disease progression, iv) to study the correlation between HIV diversity and cross clade immune responses in individuals with chronic HIV infection, v) to investigate whether being treated at primary HIV infection (PHI) for a limited duration may delay damage to the immune system and prolong time to initiation of long-term anti-HIV therapy, vi) to study immune responses to vaccine candidates, vii) to study the prevalence of pre-existing adeno virus-specific T cells and their effect on Chimp Ad vector induced immune responses. One of the major challenges of developing an HIV vaccine is the poor understanding of protective immune responses. This broad research programme contributes to solving this problem. We are using different cohorts, especially serodiscordant couples, where in the ESN we follow HIV negative individuals at regular intervals while providing HIV prevention counselling. Immune responses to HIV are investigated in both ESN and in newly infected individuals. For the adeno virus project we identified individuals in Entebbe who have been screened for pre-existing Ad-specific T cells and humoral responses. We are defining the phenotype, function and potential cross-reactivity of T cell responses generated against adenovirus serotypes AdHu5, AdC6, and AdC7 in the Ugandan population. Another study, conducted in our Rural Clinical Cohort, looks at broadly neutralizing antibodies and their association with disease progression. To look at the potential protective effects of early short-term treatment of new HIV infection with anti-retroviral drugs, we contribute to the international SPARTAC trial. Furthermore, we participate in studies to evaluate immune responses to HIV vaccines, including a phase I study to evaluate the safety and immunogenicity of ALVAC-HIV vCP 1521 in infants born to HIV-1 infected women, in whom we investigate neutralizing and binding antibodies Immunological methods used include ELISpot and flowcytometery. We have introduced the cultured IFN-gamma ELISPOT assay in which PBMC are stimulated with HIV peptides in the presence of anti-apoptotic factor (IL-7) and T cell growth factor IL-2. After 10-11 days the cells are rested for 29-34 hours in the absence of peptide stimuli or cytokines and then tested for secretion of IFN-g upon re-exposure to HIV peptides as in the ex-vivo assay. For flowcytometry, the Unit has acquired an LSR II with 4 lasers which can measure up to 18 fluorescence parameters. For the neutralizing antibodies, we use the pseudovirion neutralization assay. This programme of work is funded from different complementary sources including the MRC/UVRI Uganda Unit core budget, EDCTP, the Wellcome Trust and others.</gtr:technicalSummary><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>4425222</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>DR2 INSERM</gtr:department><gtr:description>European HIV Vaccine Alliance (EHVA) an EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates</gtr:description><gtr:id>88401CCA-0444-44B2-A5C5-C29FF9A92166</gtr:id><gtr:impact>We have worked together to apply for funding to EDCTP. We also use the funds to attend important meetings</gtr:impact><gtr:outcomeId>58cd1277404d83.22037054-1</gtr:outcomeId><gtr:partnerContribution>We provide the clinical sites and clinical trial expertise</gtr:partnerContribution><gtr:piContribution>We are providing the link with EDCTP and clinical trial sites where new products will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>World Health Organization (WHO)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Vaccine unit</gtr:department><gtr:description>Vaccine research in Africa</gtr:description><gtr:id>0786F0E4-4B56-4C96-B088-D6A28131DDAC</gtr:id><gtr:impact>Publications, training, equipments, further collaborations</gtr:impact><gtr:outcomeId>qSQbXqxYvZD-1</gtr:outcomeId><gtr:partnerContribution>Training, collaborations and networking, reagentsTraining, funding, reagents, equipmentsTraining, funding, reagents, equipments</gtr:partnerContribution><gtr:piContribution>Generation of ideas, protocol development, conduct of experiments and training</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eurovacc Foundation</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Vaccine research in Africa</gtr:description><gtr:id>8FC63FFC-24B3-434B-984D-9165E9CF256B</gtr:id><gtr:impact>Publications, training, equipments, further collaborations</gtr:impact><gtr:outcomeId>qSQbXqxYvZD-5</gtr:outcomeId><gtr:partnerContribution>Training, collaborations and networking, reagentsTraining, funding, reagents, equipmentsTraining, funding, reagents, equipments</gtr:partnerContribution><gtr:piContribution>Generation of ideas, protocol development, conduct of experiments and training</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>IAVI Clinical Trial and Laboratory Program for 2016-2017</gtr:description><gtr:id>7BE49C01-E594-44DB-9B15-8B996F42C6D2</gtr:id><gtr:impact>Publications, training and laboratory infrastructure</gtr:impact><gtr:outcomeId>58cd14199a61a9.76502901-1</gtr:outcomeId><gtr:partnerContribution>They provide funds, capacity building and networking with other vaccine Research and Development partners</gtr:partnerContribution><gtr:piContribution>We provide cohorts, epidemiological, clinical and laboratory expertise to this partnership</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Medical Affairs</gtr:department><gtr:description>HIV Vaccine research collaboration</gtr:description><gtr:id>3E0DA3E4-8C67-456C-9433-7A5F6A7C51B1</gtr:id><gtr:impact>Increased capacity in vaccine research and trials, Publications, funding, training and networking</gtr:impact><gtr:outcomeId>WvQfYCsD1gK-1</gtr:outcomeId><gtr:partnerContribution>Training, financial, GCLP, further collaborations</gtr:partnerContribution><gtr:piContribution>Generation of ideas, supervision, training, leading a trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Vaccine research in Africa</gtr:description><gtr:id>237DD83C-4716-45BF-9F79-82A1AFF916ED</gtr:id><gtr:impact>Publications, training, equipments, further collaborations</gtr:impact><gtr:outcomeId>qSQbXqxYvZD-4</gtr:outcomeId><gtr:partnerContribution>Training, collaborations and networking, reagentsTraining, funding, reagents, equipmentsTraining, funding, reagents, equipments</gtr:partnerContribution><gtr:piContribution>Generation of ideas, protocol development, conduct of experiments and training</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT)</gtr:description><gtr:id>B2E2E0E3-5057-4188-9ECF-507ACA84DAEF</gtr:id><gtr:impact>Protocol development</gtr:impact><gtr:outcomeId>58cd157893e193.10175422-1</gtr:outcomeId><gtr:partnerContribution>They provide funding, capacity building and networking with other vaccine research and development partners. They also provide the vaccines to test</gtr:partnerContribution><gtr:piContribution>We provide epidemiological, clinical and laboratory expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Vaccine research in Africa</gtr:description><gtr:id>C0563B59-9A3A-406E-A08C-6FC115C5D5FD</gtr:id><gtr:impact>Publications, training, equipments, further collaborations</gtr:impact><gtr:outcomeId>qSQbXqxYvZD-2</gtr:outcomeId><gtr:partnerContribution>Training, collaborations and networking, reagentsTraining, funding, reagents, equipmentsTraining, funding, reagents, equipments</gtr:partnerContribution><gtr:piContribution>Generation of ideas, protocol development, conduct of experiments and training</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine Johns Hopkins</gtr:department><gtr:description>Superinfection studies</gtr:description><gtr:id>49514431-22A9-4BE7-9751-6476205EAE64</gtr:id><gtr:impact>Training of staff and generation of results</gtr:impact><gtr:outcomeId>N1asAEVvQYV-2</gtr:outcomeId><gtr:partnerContribution>Training in neutralization and screening for neutralization</gtr:partnerContribution><gtr:piContribution>Provision of samples 
Clinical and epidemiological data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Virology Johannesburg</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Superinfection studies</gtr:description><gtr:id>28CD3631-A6FA-4068-BF5E-E1FBCE79D50D</gtr:id><gtr:impact>Training of staff and generation of results</gtr:impact><gtr:outcomeId>N1asAEVvQYV-1</gtr:outcomeId><gtr:partnerContribution>Training in neutralization and screening for neutralization</gtr:partnerContribution><gtr:piContribution>Provision of samples 
Clinical and epidemiological data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Vaccine research in Africa</gtr:description><gtr:id>99D17A12-15F7-43B8-B15A-5688E079E913</gtr:id><gtr:impact>Publications, training, equipments, further collaborations</gtr:impact><gtr:outcomeId>qSQbXqxYvZD-3</gtr:outcomeId><gtr:partnerContribution>Training, collaborations and networking, reagentsTraining, funding, reagents, equipmentsTraining, funding, reagents, equipments</gtr:partnerContribution><gtr:piContribution>Generation of ideas, protocol development, conduct of experiments and training</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9598ADE6-FFE1-41E8-8E44-A70F3D9D55E9</gtr:id><gtr:impact>This was an international conference attended by many international delegates

Questions from audience</gtr:impact><gtr:outcomeId>dC2t5bKnWRz</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Vaccine trial results</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>BD5BC614-70E8-4CBB-9F06-8E44C2EE1F46</gtr:id><gtr:impact>Health professionsm policy makers and media have all attended presentations of our work and trial results

Scientists, policy makers and media have visited our laboratories. Government has also promised financial support to vaccine research</gtr:impact><gtr:outcomeId>STjW36CVtti</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EDCTP</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>European Union</gtr:fundingOrg><gtr:id>18EE1FCC-01D0-44AA-A91C-A8ADD72F956E</gtr:id><gtr:outcomeId>58cd2977f3c0b2.27256516</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>These are virus molecular clones that have been prepared from individuals who have recently seroconveted in order to further characterize transmitted viruses</gtr:description><gtr:id>E68AD419-DDC7-489D-8003-2262E6E69093</gtr:id><gtr:impact>This material will lead to understanding transmitted viruses and in the development of an HIV vaccine</gtr:impact><gtr:outcomeId>GbxEBPKF4Rq</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Virus molecular clones</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1C0D8973-D2EE-494A-B847-59133BD02CA4</gtr:id><gtr:title>African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d410d465dc7e420939068f2d6c672c01"><gtr:id>d410d465dc7e420939068f2d6c672c01</gtr:id><gtr:otherNames>Kaleebu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>VGRLFfpwD32</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA288E05-C499-4B86-A2AD-B0017D3F8601</gtr:id><gtr:title>Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b1d4a56327da023eec14c05d69572b2"><gtr:id>1b1d4a56327da023eec14c05d69572b2</gtr:id><gtr:otherNames>Asiki G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_14935_25_24021306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF49408D-F9D3-4990-9BD9-779AD2EE51F4</gtr:id><gtr:title>Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96914104515cb146195c0be5168b2600"><gtr:id>96914104515cb146195c0be5168b2600</gtr:id><gtr:otherNames>Walker LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>gnPDDmwfwri</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C0BDF1D-E9FE-4D14-B9F9-E936FB97CF08</gtr:id><gtr:title>Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2740857e0a6a774e56992f6a12381e"><gtr:id>7b2740857e0a6a774e56992f6a12381e</gtr:id><gtr:otherNames>Schmidt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>546482ead4cda3.17976774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F1F4B82-4614-4A75-8B3F-D903B3D0E190</gtr:id><gtr:title>A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/376008218a5d7c1b9621c40cd3d90590"><gtr:id>376008218a5d7c1b9621c40cd3d90590</gtr:id><gtr:otherNames>Vardas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>hV91wHhARJk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D351F1AD-A369-47A9-9FC7-4F08B3CA455F</gtr:id><gtr:title>Modelling the evolution and spread of HIV immune escape mutants.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4733c7e44c2264f342e6713e0e09b0be"><gtr:id>4733c7e44c2264f342e6713e0e09b0be</gtr:id><gtr:otherNames>Fryer HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>Gc4j2fSJTPg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF476BB1-56C0-4CD9-880A-2285DCD2C851</gtr:id><gtr:title>The challenge of defining standards of prevention in HIV prevention trials.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/860d34ad7a9af5b0d4cc8ad1aff097d7"><gtr:id>860d34ad7a9af5b0d4cc8ad1aff097d7</gtr:id><gtr:otherNames>Philpott S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>AstRC5xX6rp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D689F91-049E-445C-8A99-29341B897A42</gtr:id><gtr:title>Immune activation alters cellular and humoral responses to yellow fever 17D vaccine</gtr:title><gtr:parentPublicationTitle>Journal of Clinical Investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8665b53b6db0117656bda3c69960970"><gtr:id>d8665b53b6db0117656bda3c69960970</gtr:id><gtr:otherNames>Muyanja E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546482e8747d15.95590193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDBFF431-3843-4E2C-8E51-7018473D1EBF</gtr:id><gtr:title>High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3c4061661ee504353cca342019eba87"><gtr:id>c3c4061661ee504353cca342019eba87</gtr:id><gtr:otherNames>Kiwanuka N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>pm_14935_25_23880102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>334FC04D-A012-48E5-9CAB-CA0A1C7829D3</gtr:id><gtr:title>Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d410d465dc7e420939068f2d6c672c01"><gtr:id>d410d465dc7e420939068f2d6c672c01</gtr:id><gtr:otherNames>Kaleebu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_14935_25_24091694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>661D5E6E-FBAC-4B03-AACD-DA3D37967CA1</gtr:id><gtr:title>Group M consensus Gag and Nef peptides are as efficient at detecting clade A1 and D cross-subtype T-cell functions as subtype-specific consensus peptides.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6ea74ea537c68f3a1aae2552986a964"><gtr:id>c6ea74ea537c68f3a1aae2552986a964</gtr:id><gtr:otherNames>Mugaba S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>546482e9bdec57.34947957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF471D9C-144C-48EF-87CA-3663725D80A9</gtr:id><gtr:title>Equivalence of ELISpot assays demonstrated between major HIV network laboratories.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd377576d86f19344e309de87a9a5580"><gtr:id>dd377576d86f19344e309de87a9a5580</gtr:id><gtr:otherNames>Gill DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>J2ydJjPD115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>792CB1E9-89BB-46AE-8958-78F1599DD617</gtr:id><gtr:title>Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78ebbfdee0a88e9d75639400540b0ff8"><gtr:id>78ebbfdee0a88e9d75639400540b0ff8</gtr:id><gtr:otherNames>Stevens W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>ah8BR5YZAms</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FA008CB-EFCC-4150-98ED-E96650E7C2E1</gtr:id><gtr:title>Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36e6bd83dfd373c441dfe6211f736a6c"><gtr:id>36e6bd83dfd373c441dfe6211f736a6c</gtr:id><gtr:otherNames>Chen H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>m6RnWLyKeMr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98AA9B85-CF73-4FE7-B714-F7B1848133E2</gtr:id><gtr:title>HIV vaccines: current status worldwide and in Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6af52587dac94a90b3811543d28aa3a1"><gtr:id>6af52587dac94a90b3811543d28aa3a1</gtr:id><gtr:otherNames>Fast PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pypBoCG5UDC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B7B14EC-100C-41DC-9F4E-25A0CF1F94A0</gtr:id><gtr:title>Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b70e115cb06b0ffa328618ff3e281a72"><gtr:id>b70e115cb06b0ffa328618ff3e281a72</gtr:id><gtr:otherNames>Boaz MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn><gtr:outcomeId>iZBjgN5puSM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5617334C-9D50-4050-A492-460BCABC49DE</gtr:id><gtr:title>Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9f5ab962359496d9c21a8818ec01798"><gtr:id>b9f5ab962359496d9c21a8818ec01798</gtr:id><gtr:otherNames>Jaoko W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>dqYAhYsVTvf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A9AE9DA-39DF-4497-AE63-B4DD70C0F043</gtr:id><gtr:title>CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/642cb9a312ab04364a2983c4f9f6c49f"><gtr:id>642cb9a312ab04364a2983c4f9f6c49f</gtr:id><gtr:otherNames>Karita E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>RVSy52bhEsY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C701592-35DF-4F61-9725-2FD019095DA3</gtr:id><gtr:title>Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d3fb17636d71cd9d7846c4977797bf"><gtr:id>e5d3fb17636d71cd9d7846c4977797bf</gtr:id><gtr:otherNames>Pala P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14935_25_23760253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77C578D1-D0D1-452D-84D8-702B15D09EF8</gtr:id><gtr:title>HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ae2d21d79c397f48c22b9985eccad39"><gtr:id>2ae2d21d79c397f48c22b9985eccad39</gtr:id><gtr:otherNames>Voronin Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>546482e9e24013.32845111</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U950097145</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>